NCT03838367 - Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 22, 2019

Primary Completion Date

July 15, 2022

Study Completion Date

September 16, 2022

Conditions

Triple Negative Breast Neoplasms

Interventions

DRUG

350 mg leronlimab

leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.

DRUG

525 mg leronlimab

leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.

DRUG

700 mg leronlimab

leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.

DRUG

AUC 5 Carboplatin

Carboplatin is an anticancer drug chemotherapy drug.

DRUG

Maximum Tolerated Dose (MTD) of leronlimab

The decision on the MTD will be made following the results obtained from Phase I studies

Trial Locations (2)

CD07 Investigational Site, Chicago

Quest Clinical Research, San Francisco